The Gut–Brain Axis in Dogs: Microbiome–Behavior Interactions and Clinical Implications

1. Conceptual Framework and Translational Context

1.1 A Systems View

The gut–brain axis is a systems-level integration in which intestinal microbial ecosystems interact dynamically with the neural circuits governing emotion, cognition, and behavior (Cryan & Dinan, 2012; Cryan et al., 2019). The communication is bidirectional and runs through neural, endocrine, immune, and metabolic channels, all modulated by the resident microbiota. Framed this way, behavioral phenotypes such as anxiety, impulsivity, and stress resilience emerge from interactions between learning, physiology and environment — neural circuitry, endocrine signaling, immune activation, and microbial metabolism all contributing alongside learning history — with the microbiome acting, in effect, as an endocrine and neuroactive organ.

1.2 How to Read the Evidence

One caution governs the entire article. The mechanistic pathways below — vagal signaling, HPA modulation, microbial neurotransmitter production, SCFA effects on the brain — rest on strong rodent and human work and are applied to dogs by reasonable extension, given the conservation of these systems. The canine data that do exist are correlational and small. So when this article says a pathway "operates" in dogs, it usually means "is expected to operate, by extension"; where a genuine dog study exists, it is named and its limits stated. Translating any of this to the clinic demands the same restraint (the general difficulty of pinning cause to behavior).

1.3 An Axis Is Communication, Not Control

The name describes a two-way communication system, and it is routinely read as a one-way one, in which the gut governs the brain and therefore behavior. Nothing in this literature supports that reading. The verbs that fit the evidence are contributes, modulates, is involved in and can influence; the verb that does not is determines.

The direction runs the other way just as strongly: stress alters motility, secretion and microbial composition, so behavior shapes the gut as readily as the gut shapes behavior (as the chronic stress literature sets out). A framework in which everything talks to everything is harder to summarize and closer to what has been measured.

1.4 Why This Topic Attracts Overstatement

Few areas in canine behavior combine so much mechanistic plausibility with so little species-specific evidence. The mouse work is genuinely striking, the anatomy is real, and the products are already on shelves.

That combination — a compelling story, a purchasable intervention and a thin canine literature — is the standard configuration for overstatement, and it is worth naming before the mechanism chapters begin (where the wider diet and behavior evidence is set out).

1.5 What Would Count as Evidence Here

Three tiers are worth distinguishing while reading. A composition difference between behaviorally defined groups is the weakest and the most common. A demonstrated mechanism — metabolite measured, route traced — is stronger and absent in dogs. A controlled intervention with a behavioral outcome is strongest, and exactly one exists in this species.

Most claims a reader will encounter rest on the first tier while being phrased as though they rested on the third. Keeping the three apart is the single most useful habit for reading anything in this area.

2. Neuroanatomical and Physiological Architecture

2.1 The Enteric Nervous System

The enteric nervous system (ENS), the "second brain," contains roughly 200–600 million neurons in mammals, dogs included, and operates as a semi-autonomous network within the gut wall, capable of independent reflexes such as peristalsis and secretion (Furness, 2012). Its bidirectional link to the central nervous system via the vagus nerve and spinal afferents integrates visceral states with emotional and cognitive processes — the anatomical substrate for "butterflies in the stomach" under stress.

2.2 Vagal Afferent Signaling

Roughly 70–80% of vagal fibers are afferent, carrying sensory information from the viscera to the brainstem (Berthoud & Neuhuber, 2000). This lets microbial metabolites, gut hormones, and immune signals influence central activity without crossing the blood–brain barrier. The mechanistic weight of this pathway is well demonstrated: in rodents, the behavioral effects of certain probiotics — such as reduced anxiety-like behavior — disappear when the vagus is severed (Bravo et al., 2011). In dogs, direct vagal recordings are lacking, but the anatomical and functional conservation of the vagus makes similar signaling likely.

2.3 The HPA Axis

The hypothalamic–pituitary–adrenal axis is the central stress system: CRH drives ACTH, which drives cortisol. In mice the microbiome shapes this axis profoundly — germ-free mice show exaggerated HPA stress responses that normalize after colonization with specific strains such as Bifidobacterium infantis (Sudo et al., 2004), implying microbial signals help set the stress system's reactivity. In dogs, the most direct evidence of a microbiome–stress link is that fecal microbiota structure differs between normal, phobic, and aggressive dogs in a pattern associated with adrenocortical (cortisol) activity (Mondo et al., 2020) — suggestive of the same coupling, though correlational.

2.4 Neuroimmune Signaling

The microbiome regulates immunity through gut-associated lymphoid tissue and systemic cytokines. Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) can reach the brain via circumventricular organs, active transport, or vagal afferents, influencing neuroinflammation and behavior. Chronic low-grade inflammation from dysbiosis and increased intestinal permeability is increasingly implicated in anxiety- and depression-like states in humans and animal models. In dogs, inflammatory bowel disease and chronic enteropathy are reported clinically to be accompanied by behavioral change (as with visceral pain and behavior more broadly), consistent with this gut–immune–brain pathway.

2.5 The Microbiome as a Metabolic Interface

Beyond neural and immune signaling, the microbiota produces bioactive compounds acting systemically and centrally: short-chain fatty acids (acetate, propionate, butyrate) from fiber fermentation; neurotransmitter analogues (GABA, serotonin precursors, dopamine metabolites); tryptophan metabolites (kynurenine, indoles); and secondary bile acids. These act through gene expression, receptor binding, and even epigenetic regulation (a route by which experience and environment can shape gene activity), positioning the microbiome as a genuine metabolic organ interfacing with the host's neurobiology.

2.6 The Vagus Is the Best-Evidenced Route

Of the pathways described in this chapter, the vagal one has the strongest experimental support — and it has it because a specific bacterial strain produced behavioral effects in mice that disappeared when the vagus was cut (Bravo et al., 2011).

That is what a demonstrated route looks like: an intervention, an outcome, and a manipulation that removes the effect. Nothing comparable exists for the immune or metabolic routes in any species, and nothing comparable exists for any route in dogs.

2.7 Why the Number of Pathways Is Not Reassuring

Accounts of the gut-brain axis typically list four or five routes, and the length of the list reads as strength of evidence. It is closer to the opposite: multiple candidate pathways, none of them established in the species under discussion, is a description of uncertainty about the mechanism rather than of redundancy in it.

A field that knew which route mattered would not need to list them all. That is not a criticism of the researchers, who are describing an honestly unsettled picture; it is a caution about how the list reads when it is reproduced in marketing material.

3. Microbiome–Neurotransmitter Interactions

3.1 Tryptophan Metabolism and Serotonin

Tryptophan is a key interface between microbiota and host neurochemistry, split among three competing pathways: the serotonin pathway (5-HT synthesis, mostly in gut enterochromaffin cells); the immune-modulated kynurenine pathway (yielding neuroactive quinolinic and kynurenic acids); and the exclusively microbial indole pathway. Inflammation shifts tryptophan toward kynurenine, reducing serotonin availability and accumulating neurotoxic metabolites, while in mice, spore-forming gut bacteria and their metabolites promoted serotonin production in the gut (Yano et al., 2015). Peripheral serotonin does not cross the blood–brain barrier, but it modulates the CNS indirectly via vagal, platelet, and immune routes. Since peripheral serotonin measures have been associated with canine aggression and impulsivity in correlational work (part of the neurochemistry shaping behavior), tryptophan metabolism is a natural focus.

3.2 GABAergic Modulation

GABA is the CNS's main inhibitory neurotransmitter, central to anxiety. Certain bacteria (Lactobacillus rhamnosus, L. brevis, Bifidobacterium dentium) produce GABA from glutamate, and in rodents oral L. rhamnosus altered brain GABA-receptor expression and reduced anxiety- and depression-related behavior in a vagus-dependent way (Bravo et al., 2011). The implication for canine anxiety — where GABAergic drugs are used therapeutically (anxiety has its own neurobiology) — is intriguing but, in dogs, entirely unexplored at the level of microbiome-targeted intervention.

3.3 Dopaminergic and Reward Circuits

Dopamine underlies motivation, reward learning, and impulse control (the dopaminergic basis of canine learning). The microbiota influences it indirectly — precursor availability via tyrosine, immune effects on mesolimbic function, regulation of plasticity genes — routes proposed mainly from rodent work. In dogs, this is relevant to individual differences in trainability, impulsivity, and compulsive behavior, but direct evidence linking specific taxa to canine dopaminergic function is essentially absent.

3.4 The Peripheral Serotonin Problem

The claim that gut microbes influence serotonin is often read as a claim about mood, and the two are further apart than they sound. The overwhelming majority of the body's serotonin is peripheral, where it regulates gut motility rather than affect, and it does not cross the blood-brain barrier.

Microbial regulation of serotonin biosynthesis was demonstrated in mice (Yano et al., 2015) and concerned peripheral production. Central serotonergic regulation is a separate and considerably more complex system, with its own synthesis, receptor subtypes and feedback control, and "gut serotonin sets mood" is not a summary of it. The step from a peripheral finding to a dog's emotional state involves several further assumptions, none of them tested in this species.

3.5 Precursor Availability Is Not Transmitter Function

The tryptophan account has the same structure as the dietary tryptophan claims examined elsewhere: microbes influence how much precursor is available, and precursor availability is not the rate-limiting factor for central transmitter function under ordinary conditions.

Where that argument fails for a supplement, it fails for a probiotic marketed on the same mechanism.

4. Short-Chain Fatty Acids and Neurobiological Regulation

4.1 What Short-Chain Fatty Acids Do

Short-chain fatty acids — acetate, propionate, and especially butyrate — are among the best-studied microbial metabolites. Produced by bacterial fermentation of dietary fiber, in animal and cell work they support blood–brain barrier integrity, promote a resting (non-inflammatory) state in microglia, inhibit histone deacetylases (an epigenetic effect on genes for plasticity and neurotransmission), and dampen neuroinflammation. Butyrate specifically has been shown to enhance neuroplasticity, raise BDNF, and produce antidepressant-like effects in animal models (Silva et al., 2020). It is often proposed that reduced butyrate or depletion of butyrate-producers (Faecalibacterium, Roseburia) contributes to canine anxiety and chronic stress — a mechanistically reasonable hypothesis, but one that in dogs currently rests on limited, correlational associations rather than demonstrated cause. In the largest canine dataset one association even ran the other way, with higher cowardice scores going with more butyrate producers (see 6.5).

4.2 Where the SCFA Account Comes From

The account of short-chain fatty acids as signaling molecules with central effects is drawn from general and human work (Silva, Bernardi & Frozza, 2020). No canine study has measured SCFA concentrations alongside behavior.

That matters more here than for most mechanisms, because SCFAs are the specific route by which diet is supposed to reach behavior, and diet is what owners can actually change.

4.3 Fiber Is the Practical Version

If SCFAs are the mechanism, dietary fiber is the lever, since SCFAs are produced by microbial fermentation of fermentable substrate. That is a testable prediction and it has not been tested behaviorally in dogs.

It is also the least commercially interesting version of the claim, which may be part of why it has not been tested. A finding that ordinary dietary fiber moves behavior would be considerably more useful to owners than a finding about a proprietary strain, and considerably less useful to anyone selling one.

5. Dysbiosis, Barrier Function, and Neuroinflammation

5.1 Barrier Function and Inflammation

Dysbiosis — a maladaptive shift in microbial composition and function — can disrupt intestinal barrier integrity ("leaky gut") through reduced tight-junction proteins, mucin degradation, and pathogen overgrowth. The consequences are systemic: lipopolysaccharides from Gram-negative bacteria can translocate into circulation, triggering low-grade inflammation via receptors such as TLR4, which can in turn activate microglia and alter neural signaling. This inflammatory cascade is strongly linked to anxiety-like behavior, stress hypersensitivity, and cognitive impairment in rodents and humans (Foster et al., 2017). In dogs, chronic enteropathy is reported clinically to be accompanied by behavioral change — consistent with this pathway, though far from proof of it, and equally compatible with pain and discomfort as a simpler explanation.

5.2 How Many Links the Chain Has

The sequence set out here has at least five steps: dysbiosis, increased permeability, translocation of bacterial products, immune activation, and central effects on behavior. Each has support somewhere in the literature.

A chain of individually plausible steps is not a demonstrated pathway. The probability of the whole chain holding is not the probability of its best-supported link, which is how such accounts are usually read.

5.3 Where the Term Dysbiosis Does Too Much Work

Dysbiosis names a departure from a healthy microbial community, and there is no agreed definition of a healthy canine microbiome against which to measure the departure. Composition varies enormously between healthy dogs, with diet, age, environment and geography.

A dog described as dysbiotic on a commercial test has been compared against a reference range whose derivation is rarely stated. Whether that range came from healthy dogs of the same age, diet and geography is exactly the question an owner cannot answer from the report.

6. Behavioral Phenotypes and Microbiome Correlates in Dogs

This is where the article's honesty matters most, because this is where dog-specific data actually exist — and where they are thinnest.

6.1 Anxiety and Fear

Anxiety disorders — separation anxiety, noise phobia, generalized anxiety (each with distinct neurobiology) — are among the most common canine behavior problems. The canine microbiome data on fear are thin: one study found that microbiota structure differed between normal, phobic and aggressive dogs (Mondo et al., 2020), and in working dogs microbiome markers were associated with trainer-rated cowardice and hesitation (Craddock et al., 2022). These associations cannot establish direction: dysbiosis might predispose to anxiety, anxiety-related physiology (altered motility, stress hormones) might drive dysbiosis, or both. The honest status is "correlated, cause unresolved."

6.2 Aggression and Impulsivity

Aggression is the phenotype with the most direct canine microbiome data. In a study of pit bull-type dogs seized from a dogfighting operation, gut microbiome structure differed between dogs showing conspecific aggression and those not, with specific bacterial clades stratifying the groups (Kirchoff et al., 2019); a separate study found distinct microbiota structure across normal, phobic, and aggressive dogs, linked to adrenocortical activity (Mondo et al., 2020). These are genuine dog findings — but both are small, cross-sectional, and confounded by diet, housing, medication, and history, and neither can distinguish cause from effect. It remains equally plausible that the physiological stress of aggression, or the management of aggressive dogs (confinement), reshapes the microbiome (reactivity and aggression have many drivers, from fear to pain).

6.3 Stress Reactivity and the Feedback Loop

Chronic stress is a well-established modulator of gut function, altering motility, secretion, permeability, and microbial composition via sympathetic and HPA activity. The proposed result is a self-reinforcing loop — stress induces dysbiosis, which heightens stress sensitivity through HPA priming, neuroinflammation, and altered neurotransmission (the arousal system running at a higher baseline). Breaking this cycle is a plausible target of multimodal intervention, though the loop is better documented mechanistically than measured longitudinally in dogs.

6.4 Cognitive Dysfunction in Aging

Canine cognitive dysfunction (CCD), an age-related neurodegenerative condition with parallels to Alzheimer's disease (its own clinical syndrome), is often discussed alongside age-related changes in the microbiome. Here dogs offer real, if correlational, data: gut microbiome composition has been associated with both age and memory performance in pet dogs (Kubinyi et al., 2020). Whether age-related microbial shifts contribute to cognitive decline — via neuroinflammation, oxidative stress, or reduced neuroprotective metabolites — or merely accompany it remains open, and this is where commercial claims are expanding fastest, well ahead of that evidence (see 6.7).

6.5 The Largest Canine Dataset

The biggest canine study of this kind sampled 134 working dogs and used shotgun metagenomic sequencing rather than 16S amplicon methods. Microbiome markers were statistically associated with motivation, aggression, cowardice and hesitation, sociability, and obedience to one trainer versus several, while machine-learning models showed moderate predictive capability for motivation, sociability and gastrointestinal issues and none at all for job performance or stress level (Craddock et al., 2022).

Two details matter more than the headline. The behavioral ratings came from an internally used scale rather than an externally validated one, a limitation the authors state, and higher cowardice scores were associated with higher abundance of butyrate-producing species — the opposite direction to the tidy account in which butyrate producers are protective.

6.6 What the Canine Studies Share

All four are cross-sectional comparisons of microbiome composition between behaviorally defined groups or along behavioral and cognitive measures, with different sequencing approaches, in different populations, using different behavioral classifications (Craddock et al., 2022; Kirchoff et al., 2019; Kubinyi et al., 2020; Mondo et al., 2020).

They agree that composition differs between groups. They do not agree on which taxa differ, which is what would be needed to move from an association to a target. Disagreement at that level is expected in early microbiome work and is a reason to treat any named organism in a commercial claim with suspicion.

6.7 The Aging Case Is the Weakest

Microbiome involvement in canine cognitive decline is a proposal rather than a finding. No canine study has related microbiome composition to a validated cognitive score longitudinally, and the aging literature is where commercial claims are currently expanding fastest.

That combination — thin evidence and rapid commercial growth — is the one to watch.

7. The Intervention Evidence

7.1 Why Correlation Is Not Enough Here

The canine studies discussed above compare microbiome composition between groups of dogs that differ behaviorally. That design cannot establish direction, and in this field the reverse direction is entirely plausible: a chronically stressed dog has altered gut function, so a difference in composition may be a consequence of the behavior rather than a cause.

Only an intervention can separate them. Change the microbiome, measure the behavior, compare against placebo.

7.2 The Trial That Exists

A randomized placebo-controlled trial tested a specific bacterial strain over five weeks in dogs, using both owner-reported behavioral measures and activity monitoring. The reported outcome was improvement in anxiety and aggression measures, more regular sleep, and easier adjustment when owners left the home, with no side effects reported (Bijaoui & Zimmerman, 2025).

On its face that is exactly the evidence this field has been missing: a controlled canine trial on the behavioral claim rather than another composition comparison.

The outcome measures are worth noting as well. Owner report carries most of the behavioral assessment, which is the measure most exposed to expectation effects, and activity monitoring supplies an objective supplement rather than an objective primary endpoint.

Two questions decide how much weight the behavioral result can carry, and both belong in any summary of it: who performed the behavioral assessment, and whether that person was blind to allocation. A placebo-controlled design blinds the owner to which product the dog received; it does not by itself make the behavioral coding independent of the owner, and where the owner is also the assessor the two are the same person.

7.3 Who Ran It

Both authors are affiliated with commercial entities: one with the company marketing the product, the other with the biotics company behind the strain (Bijaoui & Zimmerman, 2025).

That is disclosed in the paper and it is not a scandal. It is normal in applied nutrition research, and it is information a reader needs before weighing a positive result on a proprietary strain.

7.4 What Industry Authorship Does and Does Not Mean

It does not mean the study is wrong. Randomization and placebo control are the same procedures whoever runs them, and a manufacturer has the strongest incentive to fund the trial nobody else will pay for.

What it changes is what a single positive result can carry. Independent replication matters more when the only trial in existence was conducted by the people selling the product, and in this case no independent replication exists.

7.5 The Structural Problem

The asymmetry runs deeper than any one paper. Trials establishing that a formulation helps are commercially motivated; trials establishing that a marketed formulation does nothing are not. The literature therefore accumulates positive results on proprietary strains and almost nothing else.

An absence of negative findings in such a field is a property of the funding structure rather than evidence about the products. The same pattern is visible in canine nutrition generally, and it is the reason a positive result on a proprietary formulation should be read as a starting point rather than as a conclusion.

7.6 What Would Change the Picture

An independently funded trial, on a strain nobody owns, with blinded behavioral coding rather than owner report, and a pre-registered primary outcome. None of that is technically difficult and none of it has a funder.

Until it exists, the honest statement to an owner is that one controlled canine trial reports a benefit, that it was run by the manufacturer, and that this is the entire intervention evidence base in this species. That is not a reason to refuse a low-risk supplement to a household that wants to try one; it is a reason not to present it as treatment.

8. Evidence Hierarchy and Critical Appraisal

Applying a critical lens, the evidence sorts into clear tiers.

Strong evidence exists in rodents for a small number of mechanisms — vagally mediated behavioral effects of a bacterial strain, microbial modulation of the HPA axis, and microbial regulation of peripheral serotonin (Bravo et al., 2011; Sudo et al., 2004; Yano et al., 2015). The immune and short-chain fatty acid routes rest on consistent but less direct evidence, drawn mainly from rodents and general physiology.

Moderate evidence supports probiotic effects on behavior in rodents, and correlational links between microbiome composition and behavioral or cognitive measures in dogs (Kirchoff et al., 2019; Mondo et al., 2020; Kubinyi et al., 2020; Craddock et al., 2022), together with one manufacturer-run placebo-controlled canine trial (Bijaoui & Zimmerman, 2025).

Weak or emerging evidence characterizes any claim of causality between specific taxa and canine behavioral disorders, especially complex phenotypes like aggression; almost all dog studies to date are cross-sectional and cannot separate cause from effect.

The recurring limitations are worth stating plainly: a predominance of correlational over longitudinal or interventional designs; high inter-individual variability in canine microbiota (diet, environment, breed, age, health); many uncontrolled confounders in pet dogs; a lack of standardized behavioral metrics across studies; and limited mechanistic validation in dogs, with most insight imported from other species. These are not footnotes; they define how far the framework can currently be pushed.

8.1 Where This Article Sits on Its Own Hierarchy

Applying the evidence hierarchy set out in this chapter to the article itself is a useful exercise. The anatomy and physiology are well established across mammals. The mechanistic demonstrations are rodent. The canine evidence is four composition studies and one manufacturer-run trial.

A reader who takes away only one thing should take away that ordering, because everything else in the article is downstream of it.

The canine studies do not converge on taxa. All of them report composition differences between behaviorally defined groups or along behavioral and cognitive measures and identify different organisms (Craddock et al., 2022; Kirchoff et al., 2019; Kubinyi et al., 2020; Mondo et al., 2020), which is what would be needed to move from association to target. Where they overlap they sometimes point in opposite directions, as with butyrate producers and fearfulness.

The only intervention trial is manufacturer-run. A randomized placebo-controlled canine trial exists and both authors are commercially affiliated with the product and the strain (Bijaoui & Zimmerman, 2025). No independent replication has been published.

No canine study has measured microbial metabolites. Short-chain fatty acids are the proposed route from diet to behavior and have not been quantified alongside behavior in this species.

The decisive designs are unavailable. Germ-free comparisons and vagotomy, which carry the mouse literature, cannot be performed in companion dogs.

9. Clinical Translation and Veterinary Behavioral Medicine

9.1 Reframing Behavioral Disorders

The gut–brain framework invites a reframing: problem behaviors are neurobiological phenomena that may be shaped by the individual's physiological state — possibly including gut health — not purely learned or psychological events (behavior reflects internal state, which the outward act alone does not reveal). This does not negate learning and environment; it situates them in a broader biological context.

9.2 When to Consider Gut–Brain Involvement

Routine microbiome analysis is not yet standard, but certain presentations warrant considering a gut–brain contribution: therapy-resistant anxiety unresponsive to behavior modification and standard medication; chronic stress patterns accompanied by GI signs (diarrhea, vomiting, flatulence); sudden behavioral change without a clear environmental trigger, which may signal somatic disease; GI comorbidities such as chronic enteropathy or food-responsive diarrhea; and a history of repeated antibiotic use, which can profoundly disrupt the microbiome.

9.3 A Multimodal Framework

Where a gut–brain component is suspected, management should be multimodal: behavior modification for the learned components and coping skills; environmental management to reduce stressors and restore predictability and control; nutritional optimization with adequate prebiotic fiber to support diversity and SCFA production; targeted microbiome support (strain-specific probiotics where evidence exists, prebiotics, while fecal microbiota transplantation has no established place for behavioral indications); and pharmacological therapy when indicated, mindful of drug–microbiome interactions. The point is integration, not the replacement of behavioral care with a supplement.

9.4 What Is Reasonable to Do Now

A dog with concurrent gastrointestinal signs and behavioral change should have the gastrointestinal problem investigated and treated on its own merits. That recommendation needs no gut-brain axis to justify it, and it is the one situation in which the framework and ordinary veterinary practice point the same way.

Beyond that, appropriate dietary adjustments are generally low-risk and the evidence for behavioral benefit is thin. Not every dietary change qualifies: unbalanced home-prepared rations, extreme elimination diets and unnecessary restrictions carry real nutritional risk, and a change made for behavioral reasons should still meet the same nutritional standards as any other. Presenting it as a treatment for anxiety goes past what exists.

9.5 What to Say About Commercial Testing

Microbiome test kits for dogs are marketed with reference ranges and dysbiosis scores. Given that no agreed definition of a healthy canine microbiome exists and that composition varies widely among healthy animals, a single result has little to be interpreted against.

Repeating the test with a different provider would not produce a comparable figure, which is the same problem the telomere testing market has. Sequencing methods, reference databases and analysis pipelines all differ between providers, and none of that is visible in the report an owner receives.

9.6 Setting Expectations

Altering the microbiome is not a behavioral intervention with a predictable target. Nothing in this literature licenses the step from "this changes composition" to "this changes that behavior in this dog", and the research remains interesting rather than clinically directable. Where an owner wants to try a probiotic, the honest framing is that one manufacturer-run trial reports a benefit, that the intervention is low-risk, and that improvement over five weeks in a household that has also started paying closer attention has more than one explanation.

Recording a baseline before starting is worth more than the supplement, and costs nothing. Deciding in advance what would count as improvement, in observable terms, is what turns a household trial into information rather than an impression.

10. Which Findings Come From Which Species

10.1 The Balance in This Article

This is among the most extrapolated topics in the collection, and saying so plainly protects the parts that are canine.

10.2 What Was Established in Rodents

Germ-free mice show exaggerated HPA responses to restraint stress, reversible by colonization (Sudo et al., 2004). Vagally mediated behavioral effects of a specific bacterial strain were demonstrated in mice, with the effect abolished by vagotomy (Bravo et al., 2011). Serotonin biosynthesis regulation by gut microbes was shown in mice (Yano et al., 2015).

These are the three experimental pillars of the entire field, and all three are mouse work. The vagotomy result in particular is what makes the vagal route more than a hypothesis — in mice.

10.3 What Was Established in Humans and in General

The anatomy of vagal afferent signaling (Berthoud & Neuhuber, 2000), the enteric nervous system (Furness, 2012), the short-chain fatty acid account (Silva, Bernardi & Frozza, 2020) and the microbiota-gut-brain framework itself (Cryan & Dinan, 2012; Cryan et al., 2019; Foster, Rinaman & Cryan, 2017) are general or human.

10.4 What Was Measured in Dogs

Four composition studies: microbiome and conspecific aggression (Kirchoff, Udell & Sharpton, 2019), composition in relation to age and memory performance in pet dogs (Kubinyi et al., 2020), composition and adrenocortical activity in normal, phobic and aggressive dogs (Mondo et al., 2020), and 134 working dogs profiled by shotgun metagenomics against trainer-rated behavior (Craddock et al., 2022). Plus the single intervention trial discussed above (Bijaoui & Zimmerman, 2025).

Five canine studies, four of them cross-sectional composition comparisons. That is the entire species-specific evidence base for a topic that has generated an industry.

Set beside the anxiety, pain and sleep literatures elsewhere in this collection, which have randomized trials, validated instruments or decades of clinical observation behind them, this is among the thinnest canine evidence bases in the collection.

10.5 The Gap Nobody Can Close Cheaply

No canine study has performed a germ-free comparison, a vagotomy, a fecal transplant with behavioral outcomes, or measured microbial metabolites alongside behavior. The first two would not pass ethical review in this species.

The mechanism chapters therefore describe a coherent account of why the canine correlations might exist. They do not report mechanisms observed in dogs, and the distance between the two is larger here than in any other article in this collection.

11. Summary at a Glance

The experimental pillars are mouse work — Germ-free HPA exaggeration (Sudo et al., 2004), vagally mediated behavioral effects abolished by vagotomy (Bravo et al., 2011) and microbial regulation of serotonin biosynthesis (Yano et al., 2015) were all established in mice.

The canine evidence is four composition studies — Cross-sectional comparisons relating microbiome composition to aggression, phobia and adrenocortical activity (Kirchoff et al., 2019; Mondo et al., 2020) and to age and memory (Kubinyi et al., 2020), the largest covering 134 working dogs with trainer ratings on an internal scale (Craddock et al., 2022).

Composition is not function — What sequencing returns is which organisms are present; what the mechanistic account requires is what they produce, which is measured separately.

Direction is unestablished — A chronically stressed dog has altered gut function, so a composition difference is compatible with being a consequence of the behavior rather than a cause.

One controlled canine trial exists — A randomized placebo-controlled study over five weeks reported improvements in anxiety and aggression measures and in sleep regularity (Bijaoui & Zimmerman, 2025).

Both its authors are commercially affiliated — With the company marketing the product and the biotics company behind the strain, disclosed in the paper (Bijaoui & Zimmerman, 2025).

No independent replication exists — And the funding structure of the field makes negative results on marketed formulations unlikely to be generated at all.

The mechanism is plausible throughout and demonstrated nowhere in dogs — Every link has support in some species; the chain has not been traced end to end in this one.

12. Conclusion

The gut–brain axis offers a useful framework for thinking about canine behavior as an emergent property of integrated physiological systems rather than learning alone. In rodents, a small number of experiments show that gut microbes can influence the stress axis, behavior via the vagus nerve, and peripheral serotonin (Sudo et al., 2004; Bravo et al., 2011; Yano et al., 2015); other proposed routes rest on less direct evidence. Dogs contribute preliminary data: four cross-sectional studies relate microbiome composition to aggression, phobia and adrenocortical activity, age and memory, and trainer-rated behavior in working dogs, without agreeing on which organisms matter (Kirchoff et al., 2019; Mondo et al., 2020; Kubinyi et al., 2020; Craddock et al., 2022), and a single randomized placebo-controlled trial of a proprietary strain, run by commercially affiliated authors and not independently replicated, reports improvements in anxiety and aggression measures (Bijaoui & Zimmerman, 2025). The canine-specific evidence therefore remains thin and largely correlational, and the strongest mechanistic claims are borrowed from other species. The responsible path is to use the framework's explanatory reach while demanding high-quality evidence, interpreting correlations cautiously, investigating gastrointestinal problems on their own merits, and avoiding premature causal claims that could drive ineffective interventions. Held to that standard, the gut–brain axis moves veterinary behavioral medicine toward a more integrated, physiologically grounded understanding of behavior — without overpromising what it can yet deliver.

Key Insights (Takeaways)

• The gut–brain axis reframes canine behavior as the output of integrated physiological systems — neural, endocrine, immune, and microbial — not learning alone. Some mechanisms are well demonstrated, but mainly in rodents, and they are applied to dogs by extension.

• Dogs now have their own data, and it clusters on aggression and stress: microbiome structure differs between aggressive and non-aggressive dogs (Kirchoff et al., 2019) and across normal, phobic, and aggressive dogs in a pattern linked to cortisol activity (Mondo et al., 2020), while microbiome composition tracks age and memory in pet dogs (Kubinyi et al., 2020), and working dogs add associations with trainer-rated behavior (Craddock et al., 2022). All are correlational, and they do not agree on which organisms matter.

• The mechanistic toolkit is real: vagal signaling (severing it abolishes probiotic behavioral effects in rodents; Bravo et al., 2011), microbial tuning of the HPA axis (Sudo et al., 2004), microbial neurotransmitter and SCFA production (Yano et al., 2015; Silva et al., 2020), and dysbiosis-driven neuroinflammation (Foster et al., 2017). How much operates as described in dogs is largely untested.

• Causality is the field's weak point. Nearly all canine studies are cross-sectional and cannot tell whether dysbiosis drives behavior, behavior (and its management) drives dysbiosis, or both — and inter-individual variability plus non-standard behavioral metrics compound the problem.

• Clinically, consider a gut–brain contribution in therapy-resistant anxiety, behavior change with GI signs, or after repeated antibiotics — and respond with multimodal care (behavior modification, environment, balanced nutrition, medication as needed, and at most a probiotic presented as a low-risk trial, since the only canine trial was manufacturer-run), not a single supplement. Promise cautiously; the science is a framework, not yet a verdict.

References

Berthoud, H.-R., & Neuhuber, W. L. (2000). Functional and chemical anatomy of the afferent vagal system. Autonomic Neuroscience, 85(1–3), 1–17. https://doi.org/10.1016/S1566-0702(00)00215-0

Bijaoui, E. M. M., & Zimmerman, N. P. (2025). Efficacy of a novel Lactiplantibacillus plantarum strain (LP815) in reducing canine aggression and anxiety: A randomized placebo-controlled trial with qualitative and quantitative assessment. Animals, 15(15), 2280. https://doi.org/10.3390/ani15152280

Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., Bienenstock, J., & Cryan, J. F. (2011). Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences, 108(38), 16050–16055. https://doi.org/10.1073/pnas.1102999108

Craddock, H. A., Godneva, A., Rothschild, D., Motro, Y., Grinstein, D., Lotem-Michaeli, Y., Narkiss, T., Segal, E., & Moran-Gilad, J. (2022). Phenotypic correlates of the working dog microbiome. npj Biofilms and Microbiomes, 8, 66. https://doi.org/10.1038/s41522-022-00329-5

Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nature Reviews Neuroscience, 13(10), 701–712. https://doi.org/10.1038/nrn3346

Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., … Dinan, T. G. (2019). The microbiota-gut-brain axis. Physiological Reviews, 99(4), 1877–2013. https://doi.org/10.1152/physrev.00018.2018

Foster, J. A., Rinaman, L., & Cryan, J. F. (2017). Stress & the gut-brain axis: Regulation by the microbiome. Neurobiology of Stress, 7, 124–136. https://doi.org/10.1016/j.ynstr.2017.03.001

Furness, J. B. (2012). The enteric nervous system and neurogastroenterology. Nature Reviews Gastroenterology & Hepatology, 9(5), 286–294. https://doi.org/10.1038/nrgastro.2012.32

Kirchoff, N. S., Udell, M. A. R., & Sharpton, T. J. (2019). The gut microbiome correlates with conspecific aggression in a small population of rescued dogs (Canis familiaris). PeerJ, 7, e6103. https://doi.org/10.7717/peerj.6103

Kubinyi, E., Bel Rhali, S., Sándor, S., Szabó, A., & Felföldi, T. (2020). Gut microbiome composition is associated with age and memory performance in pet dogs. Animals, 10(9), 1488. https://doi.org/10.3390/ani10091488

Mondo, E., Barone, M., Soverini, M., D'Amico, F., Cocchi, M., Petrulli, C., Mattioli, M., Marliani, G., Candela, M., & Accorsi, P. A. (2020). Gut microbiome structure and adrenocortical activity in dogs with aggressive and phobic behavioral disorders. Heliyon, 6(1), e03311. https://doi.org/10.1016/j.heliyon.2020.e03311

Silva, Y. P., Bernardi, A., & Frozza, R. L. (2020). The role of short-chain fatty acids from gut microbiota in gut-brain communication. Frontiers in Endocrinology, 11, 25. https://doi.org/10.3389/fendo.2020.00025

Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X.-N., Kubo, C., & Koga, Y. (2004). Postnatal microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response in mice. The Journal of Physiology, 558(1), 263–275. https://doi.org/10.1113/jphysiol.2004.063388

Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015). Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell, 161(2), 264–276. https://doi.org/10.1016/j.cell.2015.02.047